Screening of genetic polymorphism of GSTP1 in colorectal cancer patients before chemotherapy could contribute to effectively decrease the occurrence of serious adverse toxicity, improve the predictive specificity for a severe event. This evidence concerns the gene GSTP1 and colorectal cancer.